<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene E484A;F486I;Y489H;N501Y literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.E484A;F486I;Y489H;N501Y</span> literature reference collection</h1>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Pseudotype for Day 152 virus from a chronically infected patient, neutralizing activity of purified IgG  from 3 donors was mostly unaffected by the single mutations (Q493K/R or N439K), but the day 152 S pseudotype was resistant to neutralization.<br/> (<a href="https://doi.org/10.1016/j.cell.2021.03.027" class="lit_link">Clark et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Pseudotype for Day 152 virus from a chronically infected patient: although mAb C1A-B12 had no activity against this pseudotype,  all three affinity optimized versions were active; the antibody containing the most mutations,  C1A-B12.3, was the most potent (IC50 <0.5 Î¼g/mL).<br/> (<a href="https://doi.org/10.1016/j.cell.2021.03.027" class="lit_link">Clark et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This Spike pseudotype for Day 152 virus from a chronically infected patient was completely resistent to REGN10933.<br/> (<a href="https://doi.org/10.1016/j.cell.2021.03.027" class="lit_link">Clark et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
